Suivre
Abonner Zentaris GmbH

Zentaris GmbH

Filtre
  • 30.03.2005 – 08:46

    AEterna Zentaris Receives First Regulatory Approval for Impavido® for Parasitic Skin Disease

    Frankfurt, Germany (ots) - AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) announced it has received Colombian Food and Drug Agency approval for Impavido® (miltefosine), to treat the cutaneous form of leishmaniasis, a severe parasitic skin disease estimated to affect millions of people worldwide. This is the first-ever approval of Impavido® for this form of ...